Eli Lilly and Company’s LLY shares have lost 8.2% in the past month. A lot of this price decline is due to the global ...

Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare company in the world, worth more than $700 billion. Over the past 12 months, however, the stock's performance has been fairly lackluster, rising ...

Some industries have escaped these moves by the administration, at least for now. One of them is the pharmaceutical industry.

The stock of U.S. pharmaceutical giant Eli Lilly (LLY) is up 3% on news that rival Pfizer (PFE) has ended development of its experimental ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

Vandana Singh Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies Even as Donald Trump paused the reciprocal tariffs ...

Across Wall Street, 44 publicly traded companies were upgraded Tuesday to an equivalent rating of "buy" or "neutral." ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 agonists could be evolving, and Eli Lilly has a high-stakes opportunity to ...

The Dow and S&P 500 wavered between gains and losses at midday Wednesday amid heightened volatility after the U.S. imposed ...

The Centers for Medicare and Medicaid Services estimates U.S. health care spending will grow 5.6% annually through 2032, ...

Over the past 12 months, however, the stock's performance has been fairly lackluster, rising by just around 6%. Investors are beginning to scoff at its expensive price tag, with Eli Lilly trading ...